Fig. 1: Brusatol inhibits viability of hematologic malignancy derived cells.

a, b A serial number of Raji (a) or LCL1 (b) cells were incubated with 100 nM Brusatol for 72 h. Cell viability was determined by detecting luminescence. Untreated cells were set as a negative control. Results are the mean ± standard error of the duplicates. *p < 0.05 and ****p < 0.0001 show the significant differences between Brusatol-treated cells and the control group. c 5000 Raji or LCL1 cells were incubated with a serial concentration of Brusatol for 72 h. Cell viability was determined by detecting luminescence and relative luminescence was shown by comparing to untreated samples. d 5000 indicated cells were untreated or treated with 100 nM Brusatol. After 72 h of incubation, cell viability was determined and shown. ALL, acute lymphoblastic leukemia; BL, Burkitt’s lymphoma; DLBCL, diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; AML, acute myeloid leukemia; MM, multiple myeloma; LCLs, lymphoblastoid cell lines. Results are the mean ± standard error of the duplicates. ***p < 0.001 and ****p < 0.0001 show the significant differences as compared to the corresponding control group. e Indicated PDXs were cultured in 96-well plates and treated with different concentrations of Brusatol for 72 h. Cell viability was monitored by testing luminescence. FL (PDX-129), B-cell Follicular lymphoma; DLBCL (PDX-223), Diffuse large B cell lymphoma; BL (PDX-255), Burkitt’s lymphoma. f LCL1 cells were untreated or treated with Brusatol (40 nM, 100 nM) for 72 h. Then cells were fixed, stained, and analyzed with flow cytometry for cell cycle assay. The subG1 population in cells was labeled as the percentage.